10x Genomics (TXG) Non-Current Deffered Revenue (2018 - 2026)

10x Genomics has disclosed Non-Current Deffered Revenue across 7 years of filings, most recently posting $10.1 million for Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $10.1 million, down 19.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.1 million (down 19.34% YoY), and the FY2025 annual result was $10.5 million, down 16.08% from the prior year.
• Non-Current Deffered Revenue came in at $10.1 million for Q1 2026 at 10x Genomics, down from $10.5 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $12.6 million in Q1 2025 to a low of $3.2 million in Q4 2022.
• The 5-year median for Non-Current Deffered Revenue is $10.9 million (2025), against an average of $10.3 million.
• Across the five-year window, Non-Current Deffered Revenue soared 178.48% in 2023 and dropped 19.34% in 2026, its largest moves.
• 10x Genomics' Non-Current Deffered Revenue stood at $3.2 million in 2022, then jumped by 178.48% to $8.8 million in 2023, then surged by 41.97% to $12.5 million in 2024, then retreated by 16.08% to $10.5 million in 2025, then decreased by 3.46% to $10.1 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $10.1 million (Q1 2026), $10.5 million (Q4 2025), and $10.9 million (Q3 2025), per Business Quant data.